Nyxoah Announces Commencement of Trading of Shares on Euronext Brussels

Nyxoah (“Nyxoah” or the “Company”) a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, is delighted to announce its flotation today on Euronext Brussels. This follows a successful placing by Bank Degroof Petercam NV/SA and Belfius Bank NV/SA, raising approximately €73.70 million, or up to €84.75 million (US$100m), assuming the exercise in full of the Over-allotment Option, for the Company before expenses, at a price of €17.00 per share.

Trading of shares will begin at 9.00 (CEST) under the ticker symbol “NYXH”.

Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “Today marks an exciting new era for Nyxoah as a publicly listed company. The money raised will enable Nyxoah to further advance on ongoing clinical evidence development, launch the US DREAM IDE pivotal trial, execute on European commercialization, further invest in R&D and scale-up the organisation to successfully embrace the future.”

The full details of the results of the offering are available in the press release issued yesterday and accessible to those eligible to view them on the investor section of the Nyxoah website at www.nyxoah.com.

             
            – ENDS –

For further information, please contact:

Nyxoah
Rémi Renard, VP Therapy Development and Education
remi.renard@nyxoah.com
+32 472 12 64 40

For media enquiries, please contact:
Consilium Strategic Communications
Amber Fennell, Ashley Tapp, Lindsey Neville, Taiana De Ruyck Soares
Nyxoah@consilium-comms.com
+44 (0)20 3709 5700

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions. Nyxoah’s lead solution is the Genio® system, a CE-validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk¹ and comorbidities including cardiovascular diseases, depression and stroke.

Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.

For more information, please visit www.nyxoah.com.